Loading
Enliven Therapeutics, Inc. Stock: price and insider trades · United States
Insider Decl.
575
Thresholds
n/a
Buy Volume
€61M
36 ops. · all time
Sell Volume
€140M
359 ops. · all time
Who traded when
BuySaleBenjamin Hohl36 sales
Lyssikatos Joseph P27 sales
Patel Anish26 sales
Helen Louise Collins22 sales
Kintz Samuel20 sales
Heyman Richard A.6 sales
+4 other insiders
Since the insiders bought
- -21.1%Entry US$21.54 · Close at T+365 US$17.00
- -30.6%Entry US$18.80 · Close at T+365 US$13.05
- +398.4%Entry US$4.44 · Close at T+365 US$22.13
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Enliven Therapeutics, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$74.62.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$41.25
Analyst consensus
13 analystsStrong buy
US$69.00Target US$74.62(+81%)US$82.00
Income statement
EBITDA-US$119.4M
Net income-US$103.7M0.0% margin
Valuation
PER (forward)-17.8x
P/Book3.4x
Beta0.34
Balance sheet & cash
Market capUS$3B
Total debtUS$399k
Free Cash Flow-US$70.5M
Debt / Equity0%
Profitability & ownership
ROE-15.3%
ROA-11.0%
% insiders6.2%
% institutions115.5%
Last declaration on 21 October 2026
Declarations575 total
6,018 shares@ US$14.850.0030% mcap2.4% of flowCommon StockSEC:0001882764-26-000009:0
6,018 shares@ US$38.47550.0077% mcap6.3% of flowCommon StockSEC:0001882764-26-000009:1
5,000 shares@ US$2.480.0004% mcap0.4% of flowCommon StockSEC:0001701247-26-000014:0
5,000 shares@ US$38.46840.0064% mcap6.1% of flowCommon StockSEC:0001701247-26-000014:1
15,000 shares@ US$37.320.020% mcap19.0% of flowCommonSEC144:0001974158-26-000109
13,000 shares@ US$15.470.0058% mcap24.9% of flowCommon StockSEC:0001533228-26-000009:0
13,000 shares@ US$46.67070.017% mcap75.1% of flowCommon StockSEC:0001533228-26-000009:1
13,000 shares@ US$46.67070.018% mcap100.0% of flowCommonSEC144:0001950047-26-009907
5,000 shares@ US$2.480.0004% mcap0.5% of flowCommon StockSEC:0001701247-26-000013:0
2,916 shares@ US$50.03120.0052% mcap6.0% of flowCommon StockSEC:0001701247-26-000013:1
1,844 shares@ US$50.70890.0033% mcap3.8% of flowCommon StockSEC:0001701247-26-000013:2
240 shares@ US$51.4820.0004% mcap0.5% of flowCommon StockSEC:0001701247-26-000013:3
3,982 shares@ US$14.850.0021% mcap1.7% of flowCommon StockSEC:0001882764-26-000008:0
3,535 shares@ US$50.02860.0063% mcap5.2% of flowCommon StockSEC:0001882764-26-000008:1
2,194 shares@ US$50.71580.0040% mcap3.3% of flowCommon StockSEC:0001882764-26-000008:2
289 shares@ US$51.49290.0005% mcap0.4% of flowCommon StockSEC:0001882764-26-000008:3
12,036 shares@ US$49.120.021% mcap17.4% of flowCommonSEC144:0001974158-26-000103
38,000 shares@ US$59.2850.067% mcap77.8% of flowCommonSEC144:0001959173-26-006749
5,000 shares@ US$2.480.0004% mcap0.6% of flowCommon StockSEC:0001701247-26-000012:0
3,900 shares@ US$58.37170.0068% mcap10.1% of flowCommon StockSEC:0001701247-26-000012:1
4,630 shares@ US$58.35170.0081% mcap8.5% of flowCommon StockSEC:0001882764-26-000007:0
1,100 shares@ US$59.34650.0020% mcap2.9% of flowCommon StockSEC:0001701247-26-000012:2
1,388 shares@ US$59.35360.0025% mcap2.6% of flowCommon StockSEC:0001882764-26-000007:1
87,373 shares@ US$2.480.0065% mcap1.1% of flowCommon StockSEC:0001865125-26-000004:0
27,567 shares@ US$25.280.021% mcap3.4% of flowCommon StockSEC:0001865125-26-000004:1
25 of 575 declarations
About Enliven Therapeutics, Inc.
From March 12, 2020 to March 16, 2020, 10 Enliven Therapeutics, Inc. insiders bought for EUR 52,404,046, including Orbimed Advisors LLC (Director) for EUR 13,319,699 on March 12, 2020 and RA Capital Management, L.P. (10% Owner) for EUR 8,964,300 on March 16, 2020. The record's 40 purchases total EUR 73,681,826 (median EUR 97,716), against 360 sales worth EUR 159,953,866 (median EUR 64,773), or 10% purchases among open-market trades.
The largest sales are Orbimed Advisors LLC's: EUR 31,254,683 on June 22, 2026 (10% Owner) and EUR 20,372,121 on May 16, 2024 (Director), the same amount on the same day also being filed by Rishi Gupta (Director). Benjamin Hohl (CHIEF FINANCIAL OFFICER) files the most, 117, of which 68 sales, ahead of Joseph P. Lyssikatos (75) and Samuel Kintz (67).
Read moreShow less
The 572 filings from 43 insiders run from 2020 to 2026, with 114 option exercises and 24 grants. 2024 is the busiest year (195), ahead of 2025 (102) and 2026 (101). Over the last twelve months: 111 filings, no purchase, 71 sales. The median delay is 2 days.
For 40 purchases with a stored 90-day result, the median is -2.6% and 35% are positive: stored past results, not a forecast. This US healthcare and pharma company is worth USD 3.0 billion; insiders hold 6.2% of the capital.
